TD Securities initiated coverage of Cronos Group with a Buy rating and C$4.50 price target. Cronos, which has "some of the most iconic Canadian cannabis brands on the market, is well-positioned to improve profitability as it scales the top-line with a lean operating cost base and leading cultivation practices, the analyst tells investors.
